Analysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $20.40

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $20.40.

TLX has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Royal Bank Of Canada lowered Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Finally, Citigroup dropped their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th.

Telix Pharmaceuticals Stock Performance

Shares of TLX stock opened at $11.82 on Friday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $12.60. The company’s 50-day simple moving average is $10.72 and its 200-day simple moving average is $9.51. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Institutional Trading of Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals during the fourth quarter worth about $89,000. Bank of America Corp DE raised its stake in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the period. OLD Mission Capital LLC bought a new position in Telix Pharmaceuticals in the fourth quarter worth about $111,000. Finally, XY Capital Ltd bought a new position in Telix Pharmaceuticals in the first quarter worth about $120,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.